Myriad Genetics Inc (NASDAQ:MYGN)
| 23.74 Delayed Data As of Mar 20 |  +0.67 / +2.90%Today’s Change | 13.92 Today|||52-Week Range 28.18 | +63.61% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $1.9B |
Company Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Contact Information
Myriad Genetics, Inc. 320 Wakara Way Salt Lake City Utah 84108 |
Employees
Shareholders
| Individual stakeholders | 8.47% |
| Mutual fund holders | 52.54% |
| Other institutional | 49.63% |
Top Executives
| Paul J. Diaz | President, Chief Executive Officer & Director |
| Nicole Lambert | Chief Operating Officer |
| R. Bryan Riggsbee | Chief Financial Officer, Treasurer & Executive VP |
| Dale Muzzey | Chief Scientific Officer |
| Kevin R. Haas | Chief Technology Officer |
